Literature DB >> 8701402

Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

M Galli1, A Grassi, T Barbui.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) and the related hemolytic uremic syndrome (HUS) are disorders characterized by thrombocytopenia, microangiopathic hemolytic anemia, a variable degree of impairment of renal function and fluctuating neurological symptoms, which are thought to be due to platelet activation and subsequent formation of thrombi in the microcirculation. Since platelet activation is accompanied by the generation of microvesicles (PMPs), we determined their presence in patients with TTP and HUS by flow cytometry. The analysis was performed in whole blood, using FITC-conjugated monoclonal antibodies (CD 42b and/or CD 61a). PMPs were discriminated from platelets on the basis of size and fluorescence profiles. Their levels in 21 normal controls ranged between 2.4% and 9.4% (mean +/- SD: 5.2 +/- 1.99%). No correlations were found with platelet number. PMPs were then evaluated in 13 patients with TTP and 2 cases of HUS. In all patients they were found higher than in controls, ranging from 11.0 to 91.1% (45.0 +/- 26.0%; p = 0.0001 vs controls). PMPs were serially measured in patients with TTP: at diagnosis a correlation between PMPs and platelet number was found (R]2 = 0.669) and the time-course showed that the improvement of both microangiopathy and clinical manifestations of cerebral and renal involvement was accompanied by a progressive normalization of PMP levels and platelet count. PMP levels were measured also in patients suffering from other forms of thrombocytopenia: they were 17 patients with idiopathic thrombocytopenic purpura and 10 patients with acute leukemias and severe thrombocytopenia during the aplastic phase following chemotherapy. PMP ranges were: 2.0-79.6% (21.6 +/- 20.8%; p = 0.001 vs controls) and 4.6-12.5% (8.8 +/- 2.4%; p = 0.0001 vs controls), respectively. No correlations were found between platelet number and the absolute number of PMPs in these 2 groups of patients. These findings show that increased levels of PMPs may be found in peripheral thrombocytopenias and suggest that their presence may be clinically relevant, particularly in the microangiopathic forms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701402

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

Review 1.  Function and clinical significance of platelet-derived microparticles.

Authors:  S Nomura
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

Review 2.  Clinical relevance of microparticles from platelets and megakaryocytes.

Authors:  Joseph E Italiano; Albert T A Mairuhu; Robert Flaumenhaft
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

3.  Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles.

Authors:  Robert Flaumenhaft; James R Dilks; Jennifer Richardson; Eva Alden; Sunita R Patel-Hett; Elisabeth Battinelli; Giannoula L Klement; Martha Sola-Visner; Joseph E Italiano
Journal:  Blood       Date:  2008-09-18       Impact factor: 22.113

Review 4.  Extracellular vesicles and blood diseases.

Authors:  Shosaku Nomura
Journal:  Int J Hematol       Date:  2017-01-27       Impact factor: 2.490

Review 5.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 6.  Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.

Authors:  Hara T Georgatzakou; Sotirios P Fortis; Effie G Papageorgiou; Marianna H Antonelou; Anastasios G Kriebardis
Journal:  Biomolecules       Date:  2022-06-08

7.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

8.  Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Majlis Svensson; Matthias Mörgelin; Catharina Svanborg; Phillip I Tarr; Jody C Mooney; Sandra L Watkins; Roger Johnson; Diana Karpman
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

9.  Cell damage at the origin of antiphospholipid antibodies and their pathogenic potential in recurrent pregnancy loss.

Authors:  V Piroux; V Eschwège; J M Freyssinet
Journal:  Infect Dis Obstet Gynecol       Date:  1997

10.  MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3.

Authors:  Hongwei Liang; Xin Yan; Yi Pan; Yongsheng Wang; Nan Wang; Limin Li; Yuan Liu; Xi Chen; Chen-Yu Zhang; Hongwei Gu; Ke Zen
Journal:  Mol Cancer       Date:  2015-03-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.